Mixed
The global prevalence of sarcopenia varies significantly (10-27%) depending on the diagnostic classification and measurement instrument used, with no single standardized criterion currently established.
Because there is no single standard for diagnosing sarcopenia, prevalence rates you see in media or different clinics will vary widely (10-27%). If you are concerned about muscle loss, ask your provider which diagnostic criteria they are using (e.g., EWGSOP2) and which tool (DXA or BIA) they used, as this determines the result. Consistency in testing is more important than comparing your result to a global average.
Using different classifications and cut-off points, the prevalence of sarcopenia varied between 10% and 27% in the studies included for meta-analysis.
Why this rating
Systematic review and meta-analysis of 151 studies (n=692,056), though with noted heterogeneity and moderate/high risk of bias in many included studies.
Source
Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta‐analysis
Fanny Petermann‐Rocha et al. · Journal of Cachexia Sarcopenia and Muscle · 2021
DOI 10.1002/jcsm.12783
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →